Table 1. Description of Each Study in the Cross Trial Safety Analysis.

Study	Sponsor	Description	Randomization/Dose	Stratification	Planned Follow-Up Time
APC	NCI and Pfizer	Comparison of 2 doses of celecoxib with placebo for the prevention of colorectal adenoma recurrence	Celecoxib 200 mg BID, celecoxib 400 mg BID, or placebo	Center; low-dose aspirin use	37 mo
PreSAP	Pfizer	Comparison of celecoxib with placebo for the prevention of colorectal adenoma recurrence	Celecoxib 400 mg QD or placebo	Country; low-dose aspirin use	37 mo
MA27	NCI, NCI of Canada, and Pfizer	Factorial design comparing 2 aromatase inhibitors with or without celecoxib in postmenopausal women with breast cancer	Factorial design: exemestane (2.5 mg/d) or anastrozole (1 mg/d); celecoxib (400 mg BID) or placebo	Lymph node status at diagnosis; adjuvant chemotherapy; low-dose aspirin use	Participants would take celecoxib for 3 y after randomization but were to be followed up until the study end, which was the time of ending treatment with aromatase inhibitor
ADAPT	NIA	Comparison of naproxen sodium, celecoxib, and placebo for the prevention of Alzheimer's disease and attenuation of age-related cognitive decline	Naproxen sodium (220 mg BID), celecoxib (200 mg BID), or placebo	Field site; age categories: 70–74 y, 75–79 y, ≥80 y	Up to 7 y
CDME	NEI	Factorial design comparing laser diode photocoagulation to focal photocoagulation and celecoxib or placebo for 3 months before and after laser coagulation	Celecoxib (200 mg BID) or placebo	None	3 y
Celecoxib/Selenium Trial	NCI	Factorial design study comparing celecoxib with placebo and selenium with placebo for the prevention of colonic polyp recurrence	Factorial design: celecoxib (400 mg QD) or placebo; selenium (200 μg/d) or placebo	Clinical center; low-dose aspirin use	3 to 5 y after randomization; the planned length of follow-up depended on the recommendation by the participant's gastrointestinal physician for a follow-up colonoscopy

NIA indicates National Institute on Aging.